FDA Drops Guide for Super-Antibodies Keeping Pets Safe and Sound
Published Date: 9/18/2026
Notice
Summary
The FDA just released a draft guide to help vets and companies test the safety of special animal medicines called veterinary monoclonal antibodies. This new guide aims to make safety testing easier and more consistent worldwide, helping get these medicines to animals faster and safer. If you’re involved in making or testing these products, send your feedback by November 17, 2026, to shape the final rules!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Harmonized Safety Tests for Animal mAbs
The FDA posted draft guidance GFI #298 (VICH GL62) to harmonize how safety testing is done for veterinary monoclonal antibody products (VMAPs). The guidance is for VMAPs intended for companion animals and livestock and says harmonized methods should make testing easier and more consistent worldwide and help get these medicines to animals faster and safer. The draft is open for comment through November 17, 2026.
No New Paperwork Burden From Guidance
The draft guidance says it contains no new collection of information but refers to previously approved FDA collections under OMB control numbers 0910-0032 and 0910-0117. That means the guidance itself does not add new federal paperwork requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-19140, Notice of Final Federal Agency Actions on Proposed Highway in Georgia
Georgia is getting a big upgrade on I-75 with new commercial vehicle lanes stretching about 41 miles through five counties. This project is officially approved, so construction can move forward, making travel smoother and safer for trucks and drivers alike. If anyone wants to challenge these decisions, they must act by February 16, 2027, or it’s a no-go!
Next: 2026-19142, 60-Day Notice of Proposed Information Collection: DS-864E, Request for Exemption From Immigrant Visa Applicant's Affidavit of Support
The Department of State wants your thoughts on a new form, DS-864E, which lets some immigrant visa applicants skip the usual financial support paperwork. This affects about 24,000 people who apply for immigrant visas and will take about an hour to complete. You’ve got until November 17, 2026, to share your feedback—no money changes yet, just a chance to shape the process!